Neurocrine Biosciences (Nasdaq: NBIX) to Ring The Nasdaq Stock Market Opening Bell
December 01 2016 - 10:00AM
What: Neurocrine Biosciences
(Nasdaq:NBIX), a company that discovers and develops innovative and
life-changing pharmaceuticals, in diseases with high unmet medical
needs, through its novel R&D platform, focused on neurological
and endocrine based diseases and disorders, will visit the Nasdaq
MarketSite in Times Square.
In honor of the occasion, Kevin Gorman, Ph.D., President
& Chief Executive Officer, will ring the Opening
Bell.
Where: Nasdaq MarketSite – 4 Times Square
– 43rd & Broadway – Broadcast Studio
When: Friday, December 2, 2016 – 9:15 a.m.
to 9:30 a.m. ET
Neurocrine Biosciences Media Contact: Jane
Sorensen (858) 617-7653 jsorensen@neurocrine.com
Nasdaq MarketSite: Emily Pan (646)
441-5120 emily.pan@nasdaq.com
Feed Information: Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media: For multimedia features such
as exclusive content, photo postings, status updates and video of
bell ceremonies, please visit our Facebook
page: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page: http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page: http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page: http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page: http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Opening
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About Neurocrine
Biosciences Neurocrine Biosciences,
Inc. discovers and develops innovative and life-changing
pharmaceuticals, in diseases with high unmet medical needs, through
its novel R&D platform, focused on neurological and endocrine
based diseases and disorders. The Company's two lead late-stage
clinical programs are elagolix, a gonadotropin-releasing hormone
antagonist for women's health that is partnered with AbbVie
Inc., and INGREZZA (valbenazine or NBI-98854), a vesicular
monoamine transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine plans to commercialize INGREZZA in the
United States upon approval by the FDA.
About Nasdaq Nasdaq (Nasdaq:NDAQ) is a
leading provider of trading, clearing, exchange technology,
listing, information and public company services across six
continents. Through its diverse portfolio of solutions, Nasdaq
enables customers to plan, optimize and execute their business
vision with confidence, using proven technologies that provide
transparency and insight for navigating today's global capital
markets. As the creator of the world's first electronic stock
market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to more than 3,700 listed companies with a market
value of $10.0 trillion and approximately 18,000 corporate clients.
To learn more, visit: nasdaq.com/ambition or business.nasdaq.com
-NDAQA-
Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From Sep 2023 to Sep 2024